years. 2015 Medicare deductibles and co-insurance rates were used to estimate spend for LAAC, acute clinical events and office visits. Average drug costs were calculated from the four states with the largest number of Medicare beneficiaries. Patient stay days were taken from HCUP and inpatient rehabilitation prospective payment system data. Clinical probabilities for LAAC and warfarin were taken from PROTECT AF 4-year data and for dabigatran from the RE-LY trial. Results: The deductible for the LAAC procedure was $1,260. This compares to an average annual acquisition cost of roughly $345 for warfarin and $1,048 for dabigatran. First year total costs were $1,734, $1,023 and $1,335, for LAAC, warfarin and dabigatran, respectively. By the end of year 2, LAAC was less expensive with total costs of $2,353 compared to $2,702 (warfarin) and $2,865 (dabigatran). By year 5, LAAC was approximately half the cost of anticoagulants. ConClusions: Patient out-of-pocket costs for stroke prevention in AF are considerable and may represent a burden for many Medicare beneficiaries living on fixed incomes. LAAC with the Watchman Device provides lifetime stroke prophylaxis without increased bleeding risk at a lower cost to patients. objeCtives: Bleeding in liver surgery can be difficult to control due to extreme vascularity and tissue fragility, including compromised liver (e.g., cancer). Blood loss may be minimized with hemostats that have rapid effect and may impact cost of care. This study estimated budget impact of using EVARREST vs. SoC in hepatic surgery based on two randomized trials. Methods: An economic analysis was developed to quantify 30-day cost impact of EVARREST from a U.S. hospital perspective. Key resources, from two randomized trials (n=180), included initial treatment, retreatment, operating time, transfusions, ventilator, and hospitalization. Transplant patients (n=6) where normal liver tissue was resected were excluded from analyses. SOC was composed mainly of manual compression alone or with hemostats. The surgical analysis included resources clinically related to significant hemostasis benefits of EVARREST (i.e. retreatment, operating time, transfusion). A hospital analysis included all resources collected. Economic analyses were completed for the following subgroups: abnormal liver, metastatic cancer, anatomic/ non-anatomic liver (classifications using IHPBA definitions), cirrhotic/steatotic liver, and if patients were obese or coagulopathic. Published U.S. costs were applied to resource use. Analysis results were weighted based on trial size. Results: The surgical analysis predicted that the EVARREST cost was offset vs. SoC with a trialweighted cost impact of $719 per patient. The hospital analysis predicted further resource reduction with EVARREST with trial-weighted cost-savings of $868 per patient. Subgroup analyses demonstrated a range of results from cost impact to cost savings with EVARREST vs. SOC (i.e., $1,976 to -$5,430 per patient, hospital analysis). EVARREST use in coagulopathic patients was found to have the largest degree of cost savings with $1,859 and $5,176 per patient anticipated, surgical and hospital results respectively. ConClusions: In addition to meeting an important unmet need in controlling problematic bleeding in liver tissue, this analysis suggests that EVARREST can be a cost saving strategy. objeCtives: Anti-epidermal growth factor receptor (EGFR) therapies are ineffective in tumors with KRAS mutations in exon 2 codons 12 and 13. Thus, guidelines have recommended determination of KRAS mutation status in metastatic colorectal cancer (mCRC). Both the cobas® KRAS Mutation Test (cobas® test, currently available as Research Use Only in the US) and the therascreen KRAS RGQ PCR Kit (therascreen test) detect KRAS mutations in exon 2; cobas® test detects twelve mutations and therascreen test detects seven mutations in exon 2. We estimated the potential clinical and budgetary impact of using the cobas® test versus therascreen test in the mCRC setting. Methods: A budget impact model comparing the clinical and economic outcomes of using the cobas® test versus therascreen test was developed from the US payer perspective. We assumed 42,000 annual cases of mCRC patients. Model inputs were obtained from literature, whereas testing and treatment costs were calculated from CMS reimbursement rates. KRAS test sensitivity reflected the test's ability to detect mutations in codons 12 and 13; specificity was assumed to be the same for both tests. The model calculated the average cost for mCRC patients over 5 years, using median time on treatment and median overall survival. Based on current practice patterns, the proportion of patients receiving KRAS testing before 1st-line, 2nd-line, and 3rd-line therapy were 42%, 32%, and 26%, respectively. Results: Adopting the cobas® test resulted in a reduction of 289 patient-months lost due to non-optimal care (i.e. by avoiding anti-EGFR therapies in mutant positive patients) and an improvement in median overall survival. Adopting the cobas® test generated a total of $2.3 million in cost savings and an average decrease of $7 per mCRC patient per month. ConClusions: Using the cobas® test with improved sensitivity was associated with a reduction of patient-month lost and a decrease of healthcare costs in mCRC patients. objeCtives: Depending on the penetration of screening recommendations, it is possible that the incidence of detected pulmonary nodules (PNs) could increase exponentially in coming years. Currently PN evaluation routinely requires costly procedures including imaging, biopsy and surgery. A molecular blood based test that measures plasma proteins using selected reaction monitoring mass spectroscopy allows for an objective and quantitative assessment of PN benignity. This budget impact analysis was performed to quantify the molecular test impact on a US commercial health plan's direct medical costs. Methods: The budget impact model was developed from a commercial health plan perspective, with direct medical costs estimated from the MarketScan® reimbursement benchmark data. Total PN diagnostic evaluation costs were estimated for a 2-year time horizon and were calculated for the current standard of care and care with the introduction of the molecular test. Diagnostic procedure resource utilization was obtained from a retrospective chart review analysis of a geographically representative sample of indeterminate PNs (8-20mm) managed by outpatient pulmonologists. Results: Currently, 52% of PNs are evaluated with an invasive procedure (biopsy/surgery) and 48% with surveillance alone, with significant cost differences observed between these two groups. The base case analysis using a health plan of one million members and a rate of 0.25% PNs within the health plan, estimated a 27% reduction in avoidable invasive procedures with the introduction of the molecular test. This amounted to a total potential cost savings of 20% from procedure and complication avoidance. ConClusions: Adoption of this molecular test may help reduce the number of unnecessary invasive procedures being performed for individuals presenting with indeterminate pulmonary nodules. The reduced resource utilization can result in cost savings for the health plan. objeCtives: There is a strong correlation between cardiovascular disease and diabetes with management of blood pressure (BP), blood glucose (BG), and lipids being essential to preventing disease progression and complications. The FDA-cleared Proteus device captures and shares information about medication-taking, rest and activity patterns through a mobile device and app, a patch with a wearable sensor inside, and sensor-enabled pills. This offering facilitates patient engagement and behavioral change, informative provider decision-making, and improvement of outcomes. An economic model was developed to estimate the impact of reducing BP, BG, and lipids via the Proteus offering. Methods: The value of 1-month use of the Proteus offering to reduce BP, BG, and lipids was evaluated in patients with comorbid hypertension, type 2 diabetes, and hypercholesterolemia from a US payer perspective for a 1-year time horizon. The clinical and utilization assumptions were derived from the literature, expert opinion, and a real-world Proteus study in patients with uncontrolled hypertension. Costs were derived from the Medicare Fee Schedule and AHRQ databases. Payers were also interviewed for current management of these conditions as input to the model. Results: The cost offsets of the Proteus service offering were estimated to be $90-185 per month of use, including current reimbursement for medications and medication adherence solutions. Medical cost savings consisting of reductions in outpatient and inpatient services, monitoring, disease management, and medication costs were estimated to be $850-980 per patient per year (PPPY), which was mainly driven by a 5-11% reduction in diabetes and CVD complications. Revenue opportunities via meeting quality measures presented an additional value equating to $80-95 PPPY, bringing the total value of the Proteus offering to $1020-1260 PPPY. ConClusions: The Proteus offering provides opportunities to mitigate the high costs of managing at-risk patients with multiple cardiometabolic comorbidities. objeCtives: Healthcare costs today are increasingly being shifted from payers to patients, yet few providers factor patient costs into treatment decisions. Recent advancements in stroke prevention in atrial fibrillation (AF) have resulted in new treatment options where previously there were few. While the clinical benefit and cost effectiveness of these treatments are supported by a growing body of evidence, the cost impact to patients has not been explored. This analysis sought to quantify patient out-of-pocket costs for three stroke prevention strategies: warfarin, dabigatran and left atrial appendage closure (LAAC) with the Watchman Device. Methods: A patient-level budget impact model was used to assess total out-of-pocket spend on treatment and treatment-related complications over five
objeCtives: Anti-epidermal growth factor receptor (EGFR) therapies are ineffective in tumors with KRAS mutations in exon 2 codons 12 and 13. Thus, guidelines have recommended determination of KRAS mutation status in metastatic colorectal cancer (mCRC). Both the cobas® KRAS Mutation Test (cobas® test, currently available as Research Use Only in the US) and the therascreen KRAS RGQ PCR Kit (therascreen test) detect KRAS mutations in exon 2; cobas® test detects twelve mutations and therascreen test detects seven mutations in exon 2. We estimated the potential clinical and budgetary impact of using the cobas® test versus therascreen test in the mCRC setting. Methods: A budget impact model comparing the clinical and economic outcomes of using the cobas® test versus therascreen test was developed from the US payer perspective. We assumed 42,000 annual cases of mCRC patients. Model inputs were obtained from literature, whereas testing and treatment costs were calculated from CMS reimbursement rates. KRAS test sensitivity reflected the test's ability to detect mutations in codons 12 and 13; specificity was assumed to be the same for both tests. The model calculated the average cost for mCRC patients over 5 years, using median time on treatment and median overall survival. Based on current practice patterns, the proportion of patients receiving KRAS testing before 1st-line, 2nd-line, and 3rd-line therapy were 42%, 32%, and 26%, respectively. Results: Adopting the cobas® test resulted in a reduction of 289 patient-months lost due to non-optimal care (i.e. by avoiding anti-EGFR therapies in mutant positive patients) and an improvement in median overall survival. Adopting the cobas® test generated a total of $2.3 million in cost savings and an average decrease of $7 per mCRC patient per month. ConClusions: Using the cobas® test with improved sensitivity was associated with a reduction of patient-month lost and a decrease of healthcare costs in mCRC patients. objeCtives: Depending on the penetration of screening recommendations, it is possible that the incidence of detected pulmonary nodules (PNs) could increase exponentially in coming years. Currently PN evaluation routinely requires costly procedures including imaging, biopsy and surgery. A molecular blood based test that measures plasma proteins using selected reaction monitoring mass spectroscopy allows for an objective and quantitative assessment of PN benignity. This budget impact analysis was performed to quantify the molecular test impact on a US commercial health plan's direct medical costs. Methods: The budget impact model was developed from a commercial health plan perspective, with direct medical costs estimated from the MarketScan® reimbursement benchmark data. Total PN diagnostic evaluation costs were estimated for a 2-year time horizon and were calculated for the current standard of care and care with the introduction of the molecular test. Diagnostic procedure resource utilization was obtained from a retrospective chart review analysis of a geographically representative sample of indeterminate PNs (8-20mm) managed by outpatient pulmonologists. Results: Currently, 52% of PNs are evaluated with an invasive procedure (biopsy/surgery) and 48% with surveillance alone, with significant cost differences observed between these two groups. The base case analysis using a health plan of one million members and a rate of 0.25% PNs within the health plan, estimated a 27% reduction in avoidable invasive procedures with the introduction of the molecular test. This amounted to a total potential cost savings of 20% from procedure and complication avoidance. ConClusions: Adoption of this molecular test may help reduce the number of unnecessary invasive procedures being performed for individuals presenting with indeterminate pulmonary nodules. The reduced resource utilization can result in cost savings for the health plan. objeCtives: There is a strong correlation between cardiovascular disease and diabetes with management of blood pressure (BP), blood glucose (BG), and lipids being essential to preventing disease progression and complications. The FDA-cleared Proteus device captures and shares information about medication-taking, rest and activity patterns through a mobile device and app, a patch with a wearable sensor inside, and sensor-enabled pills. This offering facilitates patient engagement and behavioral change, informative provider decision-making, and improvement of outcomes. An economic model was developed to estimate the impact of reducing BP, BG, and lipids via the Proteus offering. Methods: The value of 1-month use of the Proteus offering to reduce BP, BG, and lipids was evaluated in patients with comorbid hypertension, type 2 diabetes, and hypercholesterolemia from a US payer perspective for a 1-year time horizon. The clinical and utilization assumptions were derived from the literature, expert opinion, and a real-world Proteus study in patients with uncontrolled hypertension. Costs were derived from the Medicare Fee Schedule and AHRQ databases. Payers were also interviewed for current management of these conditions as input to the model. Results: The cost offsets of the Proteus service offering were estimated to be $90-185 per month of use, including current reimbursement for medications and medication adherence solutions. Medical cost savings consisting of reductions in outpatient and inpatient services, monitoring, disease management, and medication costs were estimated to be $850-980 per patient per year (PPPY), which was mainly driven by a 5-11% reduction in diabetes and CVD complications. Revenue opportunities via meeting quality measures presented an additional value equating to $80-95 PPPY, bringing the total value of the Proteus offering to $1020-1260 PPPY. ConClusions: The Proteus offering provides opportunities to mitigate the high costs of managing at-risk patients with multiple cardiometabolic comorbidities. objeCtives: Healthcare costs today are increasingly being shifted from payers to patients, yet few providers factor patient costs into treatment decisions. Recent advancements in stroke prevention in atrial fibrillation (AF) have resulted in new treatment options where previously there were few. While the clinical benefit and cost effectiveness of these treatments are supported by a growing body of evidence, the cost impact to patients has not been explored. This analysis sought to quantify patient out-of-pocket costs for three stroke prevention strategies: warfarin, dabigatran and left atrial appendage closure (LAAC) with the Watchman Device. Methods: A patient-level budget impact model was used to assess total out-of-pocket spend on treatment and treatment-related complications over five . This analysis assesses the potential economic value of using these devices when compared with other meshes and a hand-sutured fixation approach. Methods: An economic model was developed to evaluate the budget impact to hospitals adopting ETHICON SECURESTRAP™ Open Fixation Device with ETHICON PHYSIOMESH™ Open in ventral hernia repair. A 1-to 3-year time horizon was included in the Excel-based model. An increasing utilization rate for ETHICON SECURESTRAP™ Open (20% -60%), and ETHICON PHYSIOMESH™ Open (10% -30%) was assumed over 3-year horizon. Costs of the mechanical fixation device, suture supplies, mesh, OR time, anesthesia time, and potentially avoided surgical site infections were considered. The differences in total costs were calculated. Results: Based on the model inputs, a 3-year total potential saving of $240,650 was estimated for 100 annual open ventral hernia surgeries using ETHICON SECURESTRAP™ Open Fixation Device versus suture of various meshes. Over three years, although the use of ETHICON SECURESTRAP™ Open Fixation Device added $54,600 in supplies costs, this was completely offset by potential savings in OR time costs ($167,520), potential reduction in avoided surgical site infection or seroma costs due to shorter operating room time ($126,903) , and potential reduction in anesthesia costs ($17,189 objeCtives: Peripheral artery disease affects 8-10 million U.S. adults and 50% involve femoropopliteal arteries. A novel treatment, the Lutonix®035 Drug Coated Balloon PTA catheter (DCB) is indicated for percutaneous transluminal angioplasty (PTA), after pre-dilatation, of de novo or restenotic lesions up to 150mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6mm. These analyses estimated the potential cost impact of DCBs vs. current care. Methods: These economic modeled analyses compared total costs with vs. without DCBs over one year in a real-world scenario treatment mix for femoropopliteal PAD; these analyses were not based upon head-to-head clinical comparisons. For the inpatient hospital perspective, DCBs were compared with PTA, bare metal stents (BMS), drug-eluting stents (DES), covered stents (CS), and atherectomy. For the outpatient perspective, DCBs plus short spot stents were compared with BMS, DES, CS, and atherectomy. Equal distribution of treatment options in a world with vs. without DCBs was assumed. Consumable device-related costs (based upon published costs, where available) associated with initial procedures and repeat procedures (i.e., estimated target lesion revascularizations (TLRs)) were included. Average device utilization was informed by RCTs and TLR risk was derived from a network meta-analysis. Alternative analyses, including incremental reimbursement for DCBs, or different utilization/comparator assumptions, were also evaluated. Results: When including DCBs into the mix of treatments (1,000 patients) one-year cost-savings were estimated to be $74,735 and $104,688 for inpatient and outpatient hospital perspectives, respectively. Additionally, DCBs were predicted to be cost-saving in the majority of analyses vs. individual therapies (e.g., DCB vs. CS: -$2,202 to -$2,967 per patient). Alternative analyses assuming incremental reimbursement predicted that DCBs could provide even greater cost-savings under a Medicare payment scenario. ConClusions: These analyses suggest that DCBs may provide cost-savings from a hospital perspective when considering the full range of comparators. objeCtives: Sufficient tissue sample is not always available for EGFR mutation testing to direct treatment with tyrosine kinase inhibitors in NSCLC patients. We compared the impact of using the FDA-approved cobas® EGFR Mutation Test alone versus using blood-based cobas® EGFR Mutation Test as an alternative test for patients without adequate tissue sample in NSCLC patient treatment decisionmaking in the US. Methods: A decision-tree model was developed to compare testing methodologies and resulting treatment pathways in a hypothetical NSCLC US population health plan with 5 million covered lives and a baseline EGFR mutation prevalence of 16%. Inputs were based on published literature and Medicare fee schedule reimbursement. Outcomes of the model included patients with test failures, average patient survival time, and budget impact. The combination of tissue and blood-based testing were examined in four different scenarios. Results: Blood-based EGFR mutation testing is a more accessible method for identifying EGFR mutation status for patients without a tissue sample. More patients received objeCtives: Mastectomy and lumpectomy procedures are often carried out using electrocautery; however, clinical evidence has demonstrated that the use of ultrasonic energy may reduce blood loss, seroma formation, wound infection, flap necrosis, hematoma, prolonged axillary drainage and length of stay. In the Canadian healthcare environment hospitals are faced with increasingly restrictive budgets, creating a critical need to demonstrate the cost-effectiveness of new technologies. This study was conducted to determine whether the reduction in complications associated with the use of ultrasonic energy in mastectomy and lumpectomy procedures offsets the increased device costs in a Canadian hospital. Methods: We examined the budget impact of replacing electrocautery devices with ultrasonic energy in a hospital that performs 100 lumpectomies and 100 mastectomies annually. The model incorporates the costs associated with surgery, length of stay (taking into account facility and staff costs) and postoperative complications. The cost data was obtained from the Ontario Case Costing Initiative and case costing from a large Canadian hospital. Patient outcomes data was obtained from pooling published, peer reviewed literature after completing a comprehensive literature review. A multivariate sensitivity analysis was completed to ensure scientific rigour. Results: The use of electrocautery in mastectomy and lumpectomy procedures is associated with lower device costs when compared to the use of ultrasonic energy devices. However, mastectomies and lumpectomies completed with ultrasonic energy devices demonstrate reduced operating time, a reduction in length of stay and a reduction in post-operative complications which offsets the increased device costs. The model establishes that replacing electrocautery with ultrasonic devices in a Canadian hospital performing 100 mastectomies and 100 lumpectomies annually would allow for a potential cost avoidance of $171,966. ConClusions: In a Canadian hospital, the use of ultrasonic energy in mastectomy and lumpectomy procedures provides a cost savings when compared to the use of electrocautery. Ondrejicka D. A. , Hazel M. Johnson and Johnson Medical Companies, Markham, ON, Canada objeCtives: Canadian hospitals spend an estimated $111 million annually on elective AAA repair. Percutaneous endovascular abdominal aortic repair approach (PEVAR) is a new minimally invasive technique that avoids surgical cut down associated with standard endovascular AAA repair (EVAR). Innovations in access devices and low profile stent grafts have enabled the PEVAR approach. According to recent studies, PEVAR may offer substantial efficiency benefits as well as a reduction in post-operative complications and patient pain. The objective of our study was to evaluate the budget impact to a hospital of changing the technique for AAA repair from the EVAR approach to the PEVAR approach. Methods: We examined the budget impact of replacing the EVAR approach with the PEVAR approach in a Canadian hospital that performs 100 endovascular AAA repairs annually. The model incorporates the costs associated with surgery, length of stay and postoperative complications occurring within 30 days. The cost data used in the model was obtained from peer reviewed literature, the Ontario Case Costing Initiative and case costing from a large Canadian hospital. Patient outcomes data was obtained from pooling published prospective studies after completing a comprehensive literature review. A multivariate sensitivity analysis was completed. Results: The use of PEVAR in AAA repair is associated with increased access device costs when compared to the EVAR approach. However, AAA repair completed with the PEVAR approach demonstrate reduced operating time, a reduction in length of stay and time in the recovery room and a reduction in post-operative complications which offset the increased device costs. The model establishes that switching to the PEVAR approach in a Canadian hospital performing 100 AAA repairs annually would result in a potential cost avoidance of $245,130. ConClusions: A change in AAA repair technique from EVAR to PEVAR can be a cost-effective solution for Canadian hospitals. objeCtives: Diabetes (DM) is prevalent among hospitalized patients making insulin administration a regular practice in acute care. Variability in the method of administration leaves room for optimization. A budget impact model was created to evaluate the impact of passive SPN on healthcare worker safety and HRU in the acute care setting. Methods: Model inputs include fixed assumptions of insulin waste and cost, needle stick injury (NSI) rates from safety syringe (SS) and SPN, nursing time, and supply costs. Inputs were obtained from the literature and real-world pilot studies. The model compares 4 scenarios using insulin vial with SS versus using insulin pens with SPN: 1) SS+10mL vial patient supply, 2) SS+10mL vial floor stock, 3) SS+3mL vial patient supply, 4) SS+3mL vial floor stock. Results: Using insulin pens with SPN reduced NSIs, decreased nursing time, and increased injection supply cost. Insulin consumption varies based on the scenario and affects economic outcomes. When applying real-world data from a 52-bed pilot study to each scenario, annual cost savings (+) or expenditures (-) from switching to SPN are as follows: 1) +$27,622, 2) -$5,951, 3) +$18,730, 4) -$14,485. ConClusions: The cost of NSI contributes significantly to total HRU in the acute care setting in the US. Benefits of switching to SPN include reducing NSIs and decreasing nursing time needed to prepare an insulin injection. For individual patient supply scenarios (scenarios 1 and 3), switching to SPN can reduce both NSIs and total cost to the institution. It is important to note that although the real-world pilot study results above are not generalizable, the model is adaptable to any institution based on number of beds and yearly insulin consumption. NSI rates may be underestimated, and in these cases, adoption of SPN may have a positive budget impact while improving health care worker safety.
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